Based in New York, Richard DiVenuto is a Biotech-Technology entrepreneur with experience spanning California, Florida, and Boston, Massachusetts. A current focus for Richard DiVenuto in the biotechnology realm is chimeric antigen receptor (CAR) T cell therapy which addresses conditions, such as leukemia and lymphoma, that were once impossible to treat.
As described in an article published in the Nature Reviews Drug Discovery journal, allogeneic CAR T cells is a readily available product that addresses hematological malignancies. This is particularly important for rapidly progressing diseases such as acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL).
This approach uses genetically dissimilar allogeneic CAR T cells which is distinct from patient-derived autologous CAR T cell approaches. That said, the targets, such as B cell lymphomas and CD19 and CD22 in ALL, are similar. The shorter persistence offered by allogeneic CAR T cells may have an advantage in cases where the target, as with CD123, is expressed by normal cells. In several cases, the limited nature of allogeneic CAR T cell persistence may make it ideal as a bridge toward definitive allogeneic SCT therapy approaches.
A systematic allogeneic CAR T cell redosing strategy can potentially be applied in eliminating persisting cells that express target antigens. Another approach is to combine CAR T cells with various specificities to eradicate potential clones. Beyond relapsed and refractory settings, the allogeneic CAR T cell strategy may be suitable at earlier disease stages, as a way of eliminating the persisting residual disease.
As described in an article published in the Nature Reviews Drug Discovery journal, allogeneic CAR T cells is a readily available product that addresses hematological malignancies. This is particularly important for rapidly progressing diseases such as acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL).
This approach uses genetically dissimilar allogeneic CAR T cells which is distinct from patient-derived autologous CAR T cell approaches. That said, the targets, such as B cell lymphomas and CD19 and CD22 in ALL, are similar. The shorter persistence offered by allogeneic CAR T cells may have an advantage in cases where the target, as with CD123, is expressed by normal cells. In several cases, the limited nature of allogeneic CAR T cell persistence may make it ideal as a bridge toward definitive allogeneic SCT therapy approaches.
A systematic allogeneic CAR T cell redosing strategy can potentially be applied in eliminating persisting cells that express target antigens. Another approach is to combine CAR T cells with various specificities to eradicate potential clones. Beyond relapsed and refractory settings, the allogeneic CAR T cell strategy may be suitable at earlier disease stages, as a way of eliminating the persisting residual disease.
